WUXI BIO (02269): Miao Jingwen appointed as non-executive director.

19:26 20/11/2024

Wu Yibing, Ph.D., has resigned as of November 20, 2024, in an announcement from WuXi Biologics (02269).

WUXI BIO (02269) announces that, effective from November 20, 2024, Dr. Wu Yibing has resigned as a non-executive director and member of the Board's decision-making committee to dedicate more time to other personal matters. Ms. Miao Jingwen has been appointed as a non-executive director and member of the decision-making committee.

HutchMed (00013) announced the publication of the SACHI Phase III study results in The Lancet.

Shanxi Huhua Group (003002.SZ) applies for a private placement of shares, which has been accepted by the Shenzhen Stock Exchange.

HK Stock Market Move | Optical communication sector collectively rebounds, NVIDIA Rubin platform full version released, institutions optimistic about the large-scale industrialization of Scaleup CPO.

HutchMed (00013) announced the publication of the SACHI Phase III study results in The Lancet.

Shanxi Huhua Group (003002.SZ) applies for a private placement of shares, which has been accepted by the Shenzhen Stock Exchange.

HK Stock Market Move | Optical communication sector collectively rebounds, NVIDIA Rubin platform full version released, institutions optimistic about the large-scale industrialization of Scaleup CPO.